Fulgent Genetics (NASDAQ:FLGT - Get Free Report) will be releasing its earnings data before the market opens on Friday, November 8th. Analysts expect Fulgent Genetics to post earnings of ($0.19) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings results on Friday, August 2nd. The company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.45. The firm had revenue of $71.03 million for the quarter, compared to analysts' expectations of $69.07 million. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.33) earnings per share. On average, analysts expect Fulgent Genetics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Fulgent Genetics Trading Up 0.7 %
Shares of NASDAQ FLGT traded up $0.16 during mid-day trading on Friday, reaching $21.61. The company had a trading volume of 189,962 shares, compared to its average volume of 176,885. The business's 50-day moving average is $21.20 and its 200-day moving average is $21.39. Fulgent Genetics has a 52 week low of $18.76 and a 52 week high of $30.68.
Insider Transactions at Fulgent Genetics
In related news, CEO Ming Hsieh sold 2,313 shares of the company's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the sale, the chief executive officer now directly owns 707,275 shares of the company's stock, valued at $16,147,088.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 4,324 shares of company stock worth $98,717. Insiders own 31.76% of the company's stock.
About Fulgent Genetics
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Further Reading
Before you consider Fulgent Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulgent Genetics wasn't on the list.
While Fulgent Genetics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
